Hyam Levitsky - Net Worth and Insider Trading
Hyam Levitsky Net Worth
The estimated net worth of Hyam Levitsky is at least $10 Million dollars as of 2024-11-13. Hyam Levitsky is the EVP, Research & CSO of Juno Therapeutics Inc and owns about 116,700 shares of Juno Therapeutics Inc (JUNO) stock worth over $10 Million. Details can be seen in Hyam Levitsky's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Hyam Levitsky has not made any transactions after 2016-06-17 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Hyam Levitsky
Hyam Levitsky Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Hyam Levitsky owns 4 companies in total, including Replimune Group Inc (REPL) , Juno Therapeutics Inc (JUNO) , and Agenus Inc (AGEN) among others .
Click here to see the complete history of Hyam Levitsky’s form 4 insider trades.
Insider Ownership Summary of Hyam Levitsky
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| REPL | Replimune Group Inc | 2018-07-19 | director |
| JUNO | Juno Therapeutics Inc | 2017-02-07 | EVP & Research & CSO |
| AGEN | Agenus Inc | 2006-09-13 | director |
 | | 2022-01-25 | President of R&D |
Hyam Levitsky Latest Holdings Summary
Hyam Levitsky currently owns a total of 1 stock. Hyam Levitsky owns 116,700 shares of Juno Therapeutics Inc (JUNO) as of June 17, 2016, with a value of $10 Million.
Latest Holdings of Hyam Levitsky
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| JUNO | Juno Therapeutics Inc | 2016-06-17 | 116,700 | 86.96 | 10,148,232 |
Holding Weightings of Hyam Levitsky
Hyam Levitsky Form 4 Trading Tracker
According to the SEC Form 4 filings, Hyam Levitsky has made a total of 0 transactions in Juno Therapeutics Inc (JUNO) over the past 5 years. The most-recent trade in Juno Therapeutics Inc is the sale of 12,418 shares on June 17, 2016, which brought Hyam Levitsky around $531,118.
Insider Trading History of Hyam Levitsky
- 1
Hyam Levitsky Trading Performance
Hyam Levitsky Ownership Network
Ownership Network List of Hyam Levitsky
Ownership Network Relation of Hyam Levitsky
Hyam Levitsky Owned Company Details
What does Replimune Group Inc do?
Who are the key executives at Replimune Group Inc?
Hyam Levitsky is the director of Replimune Group Inc. Other key executives at Replimune Group Inc include Chief Financial Officer Emily Luisa Hill , Chief Medical Officer Konstantinos Xynos , and Chief Commercial Officer Christopher Sarchi .
Replimune Group Inc (REPL) Insider Trades Summary
Over the past 18 months, Hyam Levitsky made no insider transaction in Replimune Group Inc (REPL). Other recent insider transactions involving Replimune Group Inc (REPL) include a net sale of 51,624 shares made by Pamela Esposito , a net sale of 30,332 shares made by Konstantinos Xynos , and a net sale of 41,467 shares made by Sushil Patel .
In summary, during the past 3 months, insiders sold 8,938 shares of Replimune Group Inc (REPL) in total and bought 0 shares, with a net sale of 8,938 shares. During the past 18 months, 282,095 shares of Replimune Group Inc (REPL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 282,095 shares.
Replimune Group Inc (REPL)'s detailed insider trading history can be found in Insider Trading Tracker table.
Replimune Group Inc Insider Transactions
Hyam Levitsky Mailing Address
Above is the net worth, insider trading, and ownership report for Hyam Levitsky. You might contact Hyam Levitsky via mailing address: C/o Antigenics Inc., 162 Fifth Ave., Suite 900, New York Ny 10010.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
